Your browser doesn't support javascript.
loading
Co-design of a paediatric oncology medicines database (ProCure) to support complex care provision for children with a hard-to-treat cancer.
Mazariego, Carolyn G; McKay, Skye; Tyedmers, Elijah; Kelada, Lauren; McGill, Brittany C; Daly, Rebecca; Wakefield, Claire E; Ziegler, David S; Taylor, Natalie.
Afiliação
  • Mazariego CG; School of Population Health, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.
  • McKay S; School of Population Health, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.
  • Tyedmers E; School of Population Health, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.
  • Kelada L; School of Clinical Medicine, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia.
  • McGill BC; Kids Cancer Centre, Sydney Children's Hospital, Sydney, NSW, Australia.
  • Daly R; School of Clinical Medicine, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia.
  • Wakefield CE; Kids Cancer Centre, Sydney Children's Hospital, Sydney, NSW, Australia.
  • Ziegler DS; School of Clinical Medicine, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia.
  • Taylor N; Kids Cancer Centre, Sydney Children's Hospital, Sydney, NSW, Australia.
Front Med (Lausanne) ; 11: 1332434, 2024.
Article em En | MEDLINE | ID: mdl-38606155
ABSTRACT

Objectives:

Paediatric oncologists often encounter challenges when seeking compassionate access to off-label therapies for their patients. This study employed implementation science and co-design techniques to develop the ProCure medicines database, with the goal of streamlining the application process and addressing identified barriers in paediatric oncology.

Methods:

This study utilised an exploratory qualitative research design. Seventeen healthcare providers, including oncologists, nurse consultants, and allied health professionals, participated in semi-structured interviews guided by the Consolidated Framework for Implementation Research (CFIR) and a visual process map aid. Deductive qualitative data analysis, according to the CFIR constructs, identified key barriers and facilitators. Collaborative design sessions engaged multidisciplinary teams to develop the ProCure beta version.

Results:

Barriers to off-label therapy access included resource-intensive applications, time sensitive decision-making, and complex pharmaceutical information. Facilitators included Drug Access Navigators, Molecular Tumour Boards, and a multi-disciplinary approach. ProCure addressed end-user needs by centralising medicines information. Additional features suggested by healthcare providers included blood-brain-barrier penetrability data and successful application examples.

Conclusion:

ProCure represents a promising solution to the challenges paediatric oncologists face in accessing off-label therapies. By centralising information, it simplifies the application process, aids decision-making, and promotes a collaborative approach to patient care. The potential of the database to stream and enhance off-label therapy access underscores its relevance in improving paediatric oncology practise. Further research and implementation efforts are warranted to assess ProCure's real-world impact and refine its features based on user feedback.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália País de publicação: Suíça